IL227414A - Composition containing angiotensin type 1 receptor or its pharmacist salt and a chemokine 2 receptor or its salt, and their uses in the preparation of drugs - Google Patents

Info

Publication number

IL227414A

IL227414A IL227414A IL22741413A IL227414A IL 227414 A IL227414 A IL 227414A IL 227414 A IL227414 A IL 227414A IL 22741413 A IL22741413 A IL 22741413A IL 227414 A IL227414 A IL 227414A

Authority

IL

Israel

Prior art keywords

pharmaceutically acceptable

acceptable salt

ccr2

blocker

inhibitor

Prior art date

2011-01-11

Links

• Espacenet
• Global Dossier
• Discuss

• 102000009410 Chemokine receptor Human genes 0.000 title claims description 152
• 108050000299 Chemokine receptor Proteins 0.000 title claims description 152
• 239000003112 inhibitor Substances 0.000 title claims description 105
• 150000003839 salts Chemical class 0.000 title claims description 73
• 108050000824 Angiotensin II receptor Proteins 0.000 title claims description 38
• 102000008873 Angiotensin II receptor Human genes 0.000 title claims description 38
• 239000000203 mixture Substances 0.000 title description 43
• 239000003814 drug Substances 0.000 title description 22
• 238000002360 preparation method Methods 0.000 title description 7
• 230000037361 pathway Effects 0.000 claims description 92
• 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 65
• 229940125364 angiotensin receptor blocker Drugs 0.000 claims description 63
• 239000008194 pharmaceutical composition Substances 0.000 claims description 51
• 239000002947 C09CA04 - Irbesartan Substances 0.000 claims description 50
• 229960002198 irbesartan Drugs 0.000 claims description 50
• XEABSBMNTNXEJM-UHFFFAOYSA-N propagermanium Chemical compound OC(=O)CC[Ge](=O)O[Ge](=O)CCC(O)=O XEABSBMNTNXEJM-UHFFFAOYSA-N 0.000 claims description 49
• 229950002828 propagermanium Drugs 0.000 claims description 41
• 150000001875 compounds Chemical class 0.000 claims description 38
• 238000011282 treatment Methods 0.000 claims description 30
• 210000003734 kidney Anatomy 0.000 claims description 29
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
• 239000005557 antagonist Substances 0.000 claims description 27
• 206010012601 diabetes mellitus Diseases 0.000 claims description 25
• 201000010099 disease Diseases 0.000 claims description 24
• 208000017169 kidney disease Diseases 0.000 claims description 22
• 230000005012 migration Effects 0.000 claims description 22
• 238000013508 migration Methods 0.000 claims description 22
• 102000004169 proteins and genes Human genes 0.000 claims description 21
• 108090000623 proteins and genes Proteins 0.000 claims description 21
• 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 20
• 208000033679 diabetic kidney disease Diseases 0.000 claims description 20
• 102100022002 CD59 glycoprotein Human genes 0.000 claims description 19
• 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims description 18
• 239000000556 agonist Substances 0.000 claims description 17
• 210000001616 monocyte Anatomy 0.000 claims description 16
• 230000004913 activation Effects 0.000 claims description 15
• 230000000747 cardiac effect Effects 0.000 claims description 15
• 102100025680 Complement decay-accelerating factor Human genes 0.000 claims description 14
• 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims description 14
• 102000000018 Chemokine CCL2 Human genes 0.000 claims description 13
• 230000003399 chemotactic effect Effects 0.000 claims description 13
• 239000002552 dosage form Substances 0.000 claims description 13
• 208000001647 Renal Insufficiency Diseases 0.000 claims description 12
• 201000006370 kidney failure Diseases 0.000 claims description 12
• 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 11
• 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 11
• 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 11
• 239000005480 Olmesartan Substances 0.000 claims description 11
• 229960005117 olmesartan Drugs 0.000 claims description 11
• VUFFRQVVDOLRNK-OOQPGHNASA-N (2s,3r)-2-[[(2s)-1-[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC)C(C)C)C1=CC=C(O)C=C1 VUFFRQVVDOLRNK-OOQPGHNASA-N 0.000 claims description 10
• 201000001320 Atherosclerosis Diseases 0.000 claims description 10
• 206010020772 Hypertension Diseases 0.000 claims description 10
• 108700009885 Sar(1)-Thr(8)- angiotensin II Proteins 0.000 claims description 10
• 230000008506 pathogenesis Effects 0.000 claims description 10
• 201000001474 proteinuria Diseases 0.000 claims description 10
• 229940126662 negative allosteric modulator Drugs 0.000 claims description 9
• VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims description 9
• 208000030507 AIDS Diseases 0.000 claims description 8
• 239000002083 C09CA01 - Losartan Substances 0.000 claims description 7
• 208000020832 chronic kidney disease Diseases 0.000 claims description 7
• 229930004094 glycosylphosphatidylinositol Natural products 0.000 claims description 7
• 229940125425 inverse agonist Drugs 0.000 claims description 7
• 230000002685 pulmonary effect Effects 0.000 claims description 7
• 230000002792 vascular Effects 0.000 claims description 7
• 206010002383 Angina Pectoris Diseases 0.000 claims description 6
• 239000002053 C09CA06 - Candesartan Substances 0.000 claims description 6
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 6
• 206010019280 Heart failures Diseases 0.000 claims description 6
• 108010083387 Saralasin Proteins 0.000 claims description 6
• 229960000932 candesartan Drugs 0.000 claims description 6
• 206010061989 glomerulosclerosis Diseases 0.000 claims description 6
• 229960004773 losartan Drugs 0.000 claims description 6
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 6
• 230000002265 prevention Effects 0.000 claims description 6
• PFGWGEPQIUAZME-NXSMLHPHSA-N saralasin Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)C1=CC=C(O)C=C1 PFGWGEPQIUAZME-NXSMLHPHSA-N 0.000 claims description 6
• 229960004785 saralasin Drugs 0.000 claims description 6
• 239000005537 C09CA07 - Telmisartan Substances 0.000 claims description 5
• PJTGSIKANITYOO-RCOXNQKVSA-N N-[(1R,2S,5R)-5-[methyl(propan-2-yl)amino]-2-[(3S)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]methanesulfonamide Chemical compound CC(C)N(C)[C@@H]1CC[C@@H]([C@@H](C1)NS(C)(=O)=O)N1CC[C@H](Nc2ncnc3ccc(cc23)C(F)(F)F)C1=O PJTGSIKANITYOO-RCOXNQKVSA-N 0.000 claims description 5
• MTMDXAIUENDNDL-RJSMDTJLSA-N [(1s,3r)-3-[[(3s,4s)-3-methoxyoxan-4-yl]amino]-1-propan-2-ylcyclopentyl]-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridin-6-yl]methanone Chemical compound CO[C@@H]1COCC[C@@H]1N[C@H]1C[C@](C(=O)N2CC3=CC(=CN=C3CC2)C(F)(F)F)(C(C)C)CC1 MTMDXAIUENDNDL-RJSMDTJLSA-N 0.000 claims description 5
• 201000000306 sarcoidosis Diseases 0.000 claims description 5
• 230000008685 targeting Effects 0.000 claims description 5
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
• LUUMLYXKTPBTQR-UHFFFAOYSA-N 4-chloro-n-[5-methyl-2-(7h-pyrrolo[2,3-d]pyrimidine-4-carbonyl)pyridin-3-yl]-3-(trifluoromethyl)benzenesulfonamide Chemical compound C=1C(C)=CN=C(C(=O)C=2C=3C=CNC=3N=CN=2)C=1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 LUUMLYXKTPBTQR-UHFFFAOYSA-N 0.000 claims description 4
• 206010007558 Cardiac failure chronic Diseases 0.000 claims description 4
• 206010018364 Glomerulonephritis Diseases 0.000 claims description 4
• 208000031886 HIV Infections Diseases 0.000 claims description 4
• 208000037357 HIV infectious disease Diseases 0.000 claims description 4
• 208000002682 Hyperkalemia Diseases 0.000 claims description 4
• 206010022489 Insulin Resistance Diseases 0.000 claims description 4
• 239000002604 chemokine receptor CCR2 antagonist Substances 0.000 claims description 4
• 208000035475 disorder Diseases 0.000 claims description 4
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 4
• 208000002780 macular degeneration Diseases 0.000 claims description 4
• 201000011461 pre-eclampsia Diseases 0.000 claims description 4
• 208000024827 Alzheimer disease Diseases 0.000 claims description 3
• 206010003658 Atrial Fibrillation Diseases 0.000 claims description 3
• 206010003662 Atrial flutter Diseases 0.000 claims description 3
• 206010007559 Cardiac failure congestive Diseases 0.000 claims description 3
• 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
• 208000007530 Essential hypertension Diseases 0.000 claims description 3
• 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims description 3
• 208000019695 Migraine disease Diseases 0.000 claims description 3
• 208000021642 Muscular disease Diseases 0.000 claims description 3
• 201000009623 Myopathy Diseases 0.000 claims description 3
• 208000003782 Raynaud disease Diseases 0.000 claims description 3
• 208000012322 Raynaud phenomenon Diseases 0.000 claims description 3
• 206010039710 Scleroderma Diseases 0.000 claims description 3
• 206010039808 Secondary aldosteronism Diseases 0.000 claims description 3
• 208000006011 Stroke Diseases 0.000 claims description 3
• 206010042600 Supraventricular arrhythmias Diseases 0.000 claims description 3
• 206010047281 Ventricular arrhythmia Diseases 0.000 claims description 3
• 230000003281 allosteric effect Effects 0.000 claims description 3
• 208000010877 cognitive disease Diseases 0.000 claims description 3
• 230000003176 fibrotic effect Effects 0.000 claims description 3
• 206010020718 hyperplasia Diseases 0.000 claims description 3
• 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims description 3
• 206010027599 migraine Diseases 0.000 claims description 3
• 208000010125 myocardial infarction Diseases 0.000 claims description 3
• 208000002815 pulmonary hypertension Diseases 0.000 claims description 3
• 208000019553 vascular disease Diseases 0.000 claims description 3
• 206010020571 Hyperaldosteronism Diseases 0.000 claims description 2
• 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 2
• RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 8
• 239000004072 C09CA03 - Valsartan Substances 0.000 claims 4
• SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims 4
• YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 4
• KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 4
• 229960005187 telmisartan Drugs 0.000 claims 4
• 229960004699 valsartan Drugs 0.000 claims 4
• SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 4
• 230000001668 ameliorated effect Effects 0.000 claims 1
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 57
• YOSHYTLCDANDAN-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2NN=NN=2)C(CCCC)=NC21CCCC2 YOSHYTLCDANDAN-UHFFFAOYSA-N 0.000 description 46
• 210000004027 cell Anatomy 0.000 description 40
• 230000005764 inhibitory process Effects 0.000 description 35
• 230000000694 effects Effects 0.000 description 34
• 102000005962 receptors Human genes 0.000 description 33
• 108020003175 receptors Proteins 0.000 description 33
• 238000004519 manufacturing process Methods 0.000 description 30
• 241001465754 Metazoa Species 0.000 description 29
• 238000000034 method Methods 0.000 description 29
• 238000000225 bioluminescence resonance energy transfer Methods 0.000 description 28
• 238000009472 formulation Methods 0.000 description 27
• 241000700159 Rattus Species 0.000 description 23
• 230000001225 therapeutic effect Effects 0.000 description 21
• 102000019034 Chemokines Human genes 0.000 description 19
• 108010012236 Chemokines Proteins 0.000 description 19
• 238000000338 in vitro Methods 0.000 description 19
• 230000004044 response Effects 0.000 description 17
• 108091006027 G proteins Proteins 0.000 description 15
• 102000030782 GTP binding Human genes 0.000 description 15
• 108091000058 GTP-Binding Proteins 0.000 description 15
• 239000003826 tablet Substances 0.000 description 14
• 102000015427 Angiotensins Human genes 0.000 description 13
• 108010064733 Angiotensins Proteins 0.000 description 13
• 238000013059 nephrectomy Methods 0.000 description 13
• 239000003446 ligand Substances 0.000 description 12
• 238000005259 measurement Methods 0.000 description 12
• 238000001356 surgical procedure Methods 0.000 description 12
• 238000001890 transfection Methods 0.000 description 12
• 239000003795 chemical substances by application Substances 0.000 description 11
• 239000000843 powder Substances 0.000 description 11
• 230000007115 recruitment Effects 0.000 description 11
• -1 CD 55 Proteins 0.000 description 10
• 239000003102 growth factor Substances 0.000 description 10
• 239000000463 material Substances 0.000 description 10
• 101800000733 Angiotensin-2 Proteins 0.000 description 9
• 102400000345 Angiotensin-2 Human genes 0.000 description 9
• CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 9
• 206010061218 Inflammation Diseases 0.000 description 9
• INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 9
• 239000002253 acid Substances 0.000 description 9
• 229950006323 angiotensin ii Drugs 0.000 description 9
• 238000003556 assay Methods 0.000 description 9
• 230000004054 inflammatory process Effects 0.000 description 9
• 230000001404 mediated effect Effects 0.000 description 9
• 210000000056 organ Anatomy 0.000 description 9
• 239000013612 plasmid Substances 0.000 description 9
• 210000002784 stomach Anatomy 0.000 description 9
• 239000004094 surface-active agent Substances 0.000 description 9
• 102000002214 CXC chemokine receptor 2 Human genes 0.000 description 8
• 108010061299 CXCR4 Receptors Proteins 0.000 description 8
• 102000012000 CXCR4 Receptors Human genes 0.000 description 8
• 108010018951 Interleukin-8B Receptors Proteins 0.000 description 8
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
• 229940079593 drug Drugs 0.000 description 8
• 230000014509 gene expression Effects 0.000 description 8
• 230000007246 mechanism Effects 0.000 description 8
• 238000011160 research Methods 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 239000005541 ACE inhibitor Substances 0.000 description 7
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 7
• 208000006673 asthma Diseases 0.000 description 7
• 239000002775 capsule Substances 0.000 description 7
• 238000000576 coating method Methods 0.000 description 7
• 230000008021 deposition Effects 0.000 description 7
• 230000001434 glomerular Effects 0.000 description 7
• 230000001965 increasing effect Effects 0.000 description 7
• 210000000936 intestine Anatomy 0.000 description 7
• 230000036961 partial effect Effects 0.000 description 7
• 229920000642 polymer Polymers 0.000 description 7
• 230000011664 signaling Effects 0.000 description 7
• 210000001519 tissue Anatomy 0.000 description 7
• 102000004127 Cytokines Human genes 0.000 description 6
• 108090000695 Cytokines Proteins 0.000 description 6
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
• 229910019142 PO4 Inorganic materials 0.000 description 6
• 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 6
• 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 6
• 206010063837 Reperfusion injury Diseases 0.000 description 6
• 229920002472 Starch Polymers 0.000 description 6
• 239000002333 angiotensin II receptor antagonist Substances 0.000 description 6
• 230000004186 co-expression Effects 0.000 description 6
• 230000003247 decreasing effect Effects 0.000 description 6
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
• 239000007884 disintegrant Substances 0.000 description 6
• 239000003937 drug carrier Substances 0.000 description 6
• 238000002474 experimental method Methods 0.000 description 6
• 229920000159 gelatin Polymers 0.000 description 6
• 235000019322 gelatine Nutrition 0.000 description 6
• 239000008103 glucose Substances 0.000 description 6
• 230000006872 improvement Effects 0.000 description 6
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 6
• 210000004072 lung Anatomy 0.000 description 6
• 239000011159 matrix material Substances 0.000 description 6
• 238000000386 microscopy Methods 0.000 description 6
• 210000003205 muscle Anatomy 0.000 description 6
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
• 239000010452 phosphate Substances 0.000 description 6
• 210000000557 podocyte Anatomy 0.000 description 6
• 230000002829 reductive effect Effects 0.000 description 6
• 239000008107 starch Substances 0.000 description 6
• 235000019698 starch Nutrition 0.000 description 6
• 229940032147 starch Drugs 0.000 description 6
• 238000013268 sustained release Methods 0.000 description 6
• 239000012730 sustained-release form Substances 0.000 description 6
• 230000035488 systolic blood pressure Effects 0.000 description 6
• UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 5
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
• 206010016654 Fibrosis Diseases 0.000 description 5
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 5
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 5
• 241000282414 Homo sapiens Species 0.000 description 5
• 102000014150 Interferons Human genes 0.000 description 5
• 108010050904 Interferons Proteins 0.000 description 5
• 230000036755 cellular response Effects 0.000 description 5
• 230000006378 damage Effects 0.000 description 5
• 230000007423 decrease Effects 0.000 description 5
• 238000011161 development Methods 0.000 description 5
• 230000018109 developmental process Effects 0.000 description 5
• 230000004761 fibrosis Effects 0.000 description 5
• 239000000833 heterodimer Substances 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• 229940079322 interferon Drugs 0.000 description 5
• 150000004106 losartan derivatives Chemical class 0.000 description 5
• 230000002206 pro-fibrotic effect Effects 0.000 description 5
• 230000036454 renin-angiotensin system Effects 0.000 description 5
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
• 101150059573 AGTR1 gene Proteins 0.000 description 4
• 206010001580 Albuminuria Diseases 0.000 description 4
• 206010002091 Anaesthesia Diseases 0.000 description 4
• 108700013048 CCL2 Proteins 0.000 description 4
• 102000001417 CXC chemokine receptor 1 Human genes 0.000 description 4
• 102000010919 CXC chemokine receptor 3 Human genes 0.000 description 4
• 108010061300 CXCR3 Receptors Proteins 0.000 description 4
• 206010007572 Cardiac hypertrophy Diseases 0.000 description 4
• 208000006029 Cardiomegaly Diseases 0.000 description 4
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
• 108010010803 Gelatin Proteins 0.000 description 4
• 239000007995 HEPES buffer Substances 0.000 description 4
• 206010020751 Hypersensitivity Diseases 0.000 description 4
• 108010018976 Interleukin-8A Receptors Proteins 0.000 description 4
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• 229910052771 Terbium Inorganic materials 0.000 description 4
• 208000027418 Wounds and injury Diseases 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 230000007815 allergy Effects 0.000 description 4
• 238000001949 anaesthesia Methods 0.000 description 4
• 230000037005 anaesthesia Effects 0.000 description 4
• 230000037396 body weight Effects 0.000 description 4
• 239000004202 carbamide Substances 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 239000011248 coating agent Substances 0.000 description 4
• 230000002301 combined effect Effects 0.000 description 4
• 229940109239 creatinine Drugs 0.000 description 4
• 239000006185 dispersion Substances 0.000 description 4
• 239000008273 gelatin Substances 0.000 description 4
• 229940014259 gelatin Drugs 0.000 description 4
• 235000011852 gelatine desserts Nutrition 0.000 description 4
• 230000001976 improved effect Effects 0.000 description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
• 208000028867 ischemia Diseases 0.000 description 4
• 230000000155 isotopic effect Effects 0.000 description 4
• 230000003907 kidney function Effects 0.000 description 4
• 239000002502 liposome Substances 0.000 description 4
• 210000002540 macrophage Anatomy 0.000 description 4
• 210000004379 membrane Anatomy 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 239000006199 nebulizer Substances 0.000 description 4
• 108090000765 processed proteins & peptides Proteins 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 238000012552 review Methods 0.000 description 4
• 206010039073 rheumatoid arthritis Diseases 0.000 description 4
• GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 238000003146 transient transfection Methods 0.000 description 4
• 239000003981 vehicle Substances 0.000 description 4
• ASSJTMUEFHUKMJ-UHFFFAOYSA-N 1-acetyl-n-[3-[4-[(4-carbamoylphenyl)methyl]piperidin-1-yl]propyl]-n-(3-chloro-4-methylphenyl)piperidine-4-carboxamide Chemical compound C1CN(C(=O)C)CCC1C(=O)N(C=1C=C(Cl)C(C)=CC=1)CCCN1CCC(CC=2C=CC(=CC=2)C(N)=O)CC1 ASSJTMUEFHUKMJ-UHFFFAOYSA-N 0.000 description 3
• ZGFJFBOLVLFLLN-ZNLRHDTNSA-N 4-(4-chlorophenyl)-1-[(3e)-3-[9-(2-hydroxypropan-2-yl)-5h-[1]benzoxepino[3,4-b]pyridin-11-ylidene]propyl]-3,3-dimethylpiperidin-4-ol Chemical compound C12=CC(C(C)(O)C)=CC=C2OCC2=NC=CC=C2\C1=C/CCN(CC1(C)C)CCC1(O)C1=CC=C(Cl)C=C1 ZGFJFBOLVLFLLN-ZNLRHDTNSA-N 0.000 description 3
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
• 102000003916 Arrestin Human genes 0.000 description 3
• 108090000328 Arrestin Proteins 0.000 description 3
• 108091008927 CC chemokine receptors Proteins 0.000 description 3
• 102000005674 CCR Receptors Human genes 0.000 description 3
• 102000004497 CCR2 Receptors Human genes 0.000 description 3
• 108010017312 CCR2 Receptors Proteins 0.000 description 3
• 102000018194 CXC chemokine receptor 6 Human genes 0.000 description 3
• 108010061304 CXCR6 Receptors Proteins 0.000 description 3
• GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 3
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 3
• 241000725303 Human immunodeficiency virus Species 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• 101100194024 Metacordyceps chlamydosporia rdc1 gene Proteins 0.000 description 3
• 241000699670 Mus sp. Species 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 206010063897 Renal ischaemia Diseases 0.000 description 3
• 206010039085 Rhinitis allergic Diseases 0.000 description 3
• 229930006000 Sucrose Natural products 0.000 description 3
• 206010046851 Uveitis Diseases 0.000 description 3
• 210000001015 abdomen Anatomy 0.000 description 3
• 238000009825 accumulation Methods 0.000 description 3
• 208000026935 allergic disease Diseases 0.000 description 3
• 201000010105 allergic rhinitis Diseases 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 230000008485 antagonism Effects 0.000 description 3
• 230000036523 atherogenesis Effects 0.000 description 3
• 102000007378 beta-Arrestin 1 Human genes 0.000 description 3
• 108010032969 beta-Arrestin 1 Proteins 0.000 description 3
• 230000027455 binding Effects 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 230000033228 biological regulation Effects 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 230000036772 blood pressure Effects 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• PNDKCRDVVKJPKG-WHERJAGFSA-N cenicriviroc Chemical compound C1=CC(OCCOCCCC)=CC=C1C1=CC=C(N(CC(C)C)CCC\C(=C/2)C(=O)NC=3C=CC(=CC=3)[S@@](=O)CC=3N(C=NC=3)CCC)C\2=C1 PNDKCRDVVKJPKG-WHERJAGFSA-N 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 238000002648 combination therapy Methods 0.000 description 3
• 239000004074 complement inhibitor Substances 0.000 description 3
• 238000007906 compression Methods 0.000 description 3
• 230000006835 compression Effects 0.000 description 3
• 230000008878 coupling Effects 0.000 description 3
• 238000010168 coupling process Methods 0.000 description 3
• 238000005859 coupling reaction Methods 0.000 description 3
• 230000003111 delayed effect Effects 0.000 description 3
• 230000002939 deleterious effect Effects 0.000 description 3
• 239000003599 detergent Substances 0.000 description 3
• 235000005911 diet Nutrition 0.000 description 3
• 230000037213 diet Effects 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 239000000539 dimer Substances 0.000 description 3
• AYXBAIULRDEVAS-UHFFFAOYSA-N dimethyl-[[4-[[3-(4-methylphenyl)-8,9-dihydro-7h-benzo[7]annulene-6-carbonyl]amino]phenyl]methyl]-(oxan-4-yl)azanium;iodide Chemical compound [I-].C1=CC(C)=CC=C1C1=CC=C(CCCC(=C2)C(=O)NC=3C=CC(C[N+](C)(C)C4CCOCC4)=CC=3)C2=C1 AYXBAIULRDEVAS-UHFFFAOYSA-N 0.000 description 3
• 230000035622 drinking Effects 0.000 description 3
• 238000005538 encapsulation Methods 0.000 description 3
• 238000009505 enteric coating Methods 0.000 description 3
• 239000002702 enteric coating Substances 0.000 description 3
• OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 3
• 210000002744 extracellular matrix Anatomy 0.000 description 3
• 229910052732 germanium Inorganic materials 0.000 description 3
• GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 3
• 125000005842 heteroatom Chemical group 0.000 description 3
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
• 238000003364 immunohistochemistry Methods 0.000 description 3
• 208000027866 inflammatory disease Diseases 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 229960000367 inositol Drugs 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• PSIFNNKUMBGKDQ-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 PSIFNNKUMBGKDQ-UHFFFAOYSA-N 0.000 description 3
• 229920000609 methyl cellulose Polymers 0.000 description 3
• 235000010981 methylcellulose Nutrition 0.000 description 3
• 239000001923 methylcellulose Substances 0.000 description 3
• 239000004005 microsphere Substances 0.000 description 3
• 238000010172 mouse model Methods 0.000 description 3
• ZNSVOHSYDRPBGI-CBQRAPNFSA-N n-[2-[(3s)-3-[[4-hydroxy-4-(5-pyrimidin-2-ylpyridin-2-yl)cyclohexyl]amino]pyrrolidin-1-yl]-2-oxoethyl]-3-(trifluoromethyl)benzamide Chemical compound C([C@@H](C1)NC2CCC(CC2)(O)C=2N=CC(=CC=2)C=2N=CC=CN=2)CN1C(=O)CNC(=O)C1=CC=CC(C(F)(F)F)=C1 ZNSVOHSYDRPBGI-CBQRAPNFSA-N 0.000 description 3
• 239000002245 particle Substances 0.000 description 3
• 230000007170 pathology Effects 0.000 description 3
• YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 230000000750 progressive effect Effects 0.000 description 3
• 239000003380 propellant Substances 0.000 description 3
• 235000019260 propionic acid Nutrition 0.000 description 3
• 229940084898 proxigermanium Drugs 0.000 description 3
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
• 238000003127 radioimmunoassay Methods 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 210000002254 renal artery Anatomy 0.000 description 3
• KQDRVXQXKZXMHP-LLVKDONJSA-N reparixin Chemical compound CC(C)CC1=CC=C([C@@H](C)C(=O)NS(C)(=O)=O)C=C1 KQDRVXQXKZXMHP-LLVKDONJSA-N 0.000 description 3
• 230000000979 retarding effect Effects 0.000 description 3
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
• 239000011257 shell material Substances 0.000 description 3
• 230000019491 signal transduction Effects 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 239000007909 solid dosage form Substances 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 230000002195 synergetic effect Effects 0.000 description 3
• 230000001960 triggered effect Effects 0.000 description 3
• 230000003827 upregulation Effects 0.000 description 3
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 2
• WVLHHLRVNDMIAR-IBGZPJMESA-N AMD 070 Chemical compound C1CCC2=CC=CN=C2[C@H]1N(CCCCN)CC1=NC2=CC=CC=C2N1 WVLHHLRVNDMIAR-IBGZPJMESA-N 0.000 description 2
• 206010003210 Arteriosclerosis Diseases 0.000 description 2
• 241000416162 Astragalus gummifer Species 0.000 description 2
• 239000002080 C09CA02 - Eprosartan Substances 0.000 description 2
• 102000018211 CC chemokine receptor 1 Human genes 0.000 description 2
• 102000010494 CC chemokine receptor 10 Human genes 0.000 description 2
• 102000018201 CC chemokine receptor 3 Human genes 0.000 description 2
• 102000018348 CC chemokine receptor 5 Human genes 0.000 description 2
• 102000011400 CC chemokine receptor 7 Human genes 0.000 description 2
• 102000011005 CC chemokine receptor 8 Human genes 0.000 description 2
• 102000004900 CC chemokine receptor 9 Human genes 0.000 description 2
• 108090001026 CC chemokine receptor 9 Proteins 0.000 description 2
• 108010017319 CCR1 Receptors Proteins 0.000 description 2
• 108010088144 CCR10 Receptors Proteins 0.000 description 2
• 108010017316 CCR3 Receptors Proteins 0.000 description 2
• 108010017088 CCR5 Receptors Proteins 0.000 description 2
• 108010017158 CCR7 Receptors Proteins 0.000 description 2
• 108010017148 CCR8 Receptors Proteins 0.000 description 2
• 102000019352 CXC chemokine receptor 5 Human genes 0.000 description 2
• 108091008928 CXC chemokine receptors Proteins 0.000 description 2
• 102000054900 CXCR Receptors Human genes 0.000 description 2
• 101150004010 CXCR3 gene Proteins 0.000 description 2
• 108010061298 CXCR5 Receptors Proteins 0.000 description 2
• 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
• GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
• 206010008909 Chronic Hepatitis Diseases 0.000 description 2
• 229920000742 Cotton Polymers 0.000 description 2
• 208000011231 Crohn disease Diseases 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• 208000002249 Diabetes Complications Diseases 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 239000001856 Ethyl cellulose Substances 0.000 description 2
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
• 239000001828 Gelatine Substances 0.000 description 2
• 108010054147 Hemoglobins Proteins 0.000 description 2
• 102000001554 Hemoglobins Human genes 0.000 description 2
• 208000032843 Hemorrhage Diseases 0.000 description 2
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
• 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 2
• 101000841411 Homo sapiens Protein ecdysoneless homolog Proteins 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 102100025390 Integrin beta-2 Human genes 0.000 description 2
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
• 208000005777 Lupus Nephritis Diseases 0.000 description 2
• 229940123313 MCP-1 antagonist Drugs 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• 229930195725 Mannitol Natural products 0.000 description 2
• 101100033674 Mus musculus Ren2 gene Proteins 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• 208000022873 Ocular disease Diseases 0.000 description 2
• 108091000080 Phosphotransferase Proteins 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 229920000954 Polyglycolide Polymers 0.000 description 2
• 102100029090 Protein ecdysoneless homolog Human genes 0.000 description 2
• 206010061481 Renal injury Diseases 0.000 description 2
• 108090000783 Renin Proteins 0.000 description 2
• 102100028255 Renin Human genes 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
• 208000007536 Thrombosis Diseases 0.000 description 2
• 229920001615 Tragacanth Polymers 0.000 description 2
• 108091023040 Transcription factor Proteins 0.000 description 2
• 102000040945 Transcription factor Human genes 0.000 description 2
• 229920004890 Triton X-100 Polymers 0.000 description 2
• 239000013504 Triton X-100 Substances 0.000 description 2
• 241000545067 Venus Species 0.000 description 2
• 102000011012 XC chemokine receptor 1 Human genes 0.000 description 2
• 108050001086 XC chemokine receptor 1 Proteins 0.000 description 2
• 230000001594 aberrant effect Effects 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 239000013566 allergen Substances 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 208000011775 arteriosclerosis disease Diseases 0.000 description 2
• 210000001367 artery Anatomy 0.000 description 2
• 206010003246 arthritis Diseases 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• 230000002238 attenuated effect Effects 0.000 description 2
• 229940000201 avapro Drugs 0.000 description 2
• 238000004166 bioassay Methods 0.000 description 2
• 238000010256 biochemical assay Methods 0.000 description 2
• 230000015572 biosynthetic process Effects 0.000 description 2
• 230000000740 bleeding effect Effects 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 229960001736 buprenorphine Drugs 0.000 description 2
• 230000003491 cAMP production Effects 0.000 description 2
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
• 239000012876 carrier material Substances 0.000 description 2
• 239000004359 castor oil Substances 0.000 description 2
• 235000019438 castor oil Nutrition 0.000 description 2
• 125000002091 cationic group Chemical group 0.000 description 2
• 238000000423 cell based assay Methods 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 230000030570 cellular localization Effects 0.000 description 2
• 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 108010089833 chemokine receptor D6 Proteins 0.000 description 2
• 229960003260 chlorhexidine Drugs 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 208000037976 chronic inflammation Diseases 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 238000009792 diffusion process Methods 0.000 description 2
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 2
• 239000002612 dispersion medium Substances 0.000 description 2
• 238000004090 dissolution Methods 0.000 description 2
• 210000001198 duodenum Anatomy 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 229960004563 eprosartan Drugs 0.000 description 2
• 235000019325 ethyl cellulose Nutrition 0.000 description 2
• 229920001249 ethyl cellulose Polymers 0.000 description 2
• 230000005284 excitation Effects 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 238000009501 film coating Methods 0.000 description 2
• 239000007888 film coating Substances 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
• 235000013355 food flavoring agent Nutrition 0.000 description 2
• 229940093626 germanium sesquioxide Drugs 0.000 description 2
• 230000024924 glomerular filtration Effects 0.000 description 2
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 208000019622 heart disease Diseases 0.000 description 2
• 208000006454 hepatitis Diseases 0.000 description 2
• 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 229940060367 inert ingredients Drugs 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 230000008595 infiltration Effects 0.000 description 2
• 238000001764 infiltration Methods 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 229940125396 insulin Drugs 0.000 description 2
• 229960002725 isoflurane Drugs 0.000 description 2
• 210000000244 kidney pelvis Anatomy 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 239000007937 lozenge Substances 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 239000012139 lysis buffer Substances 0.000 description 2
• 239000011777 magnesium Substances 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• 238000007726 management method Methods 0.000 description 2
• 239000000594 mannitol Substances 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• 229940071648 metered dose inhaler Drugs 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• NXZNYBUBXWWKCP-JMOWIOHXSA-N n-[2-[[(3r)-1-[4-hydroxy-4-(6-methoxypyridin-3-yl)cyclohexyl]pyrrolidin-3-yl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide Chemical compound C1=NC(OC)=CC=C1C1(O)CCC(N2C[C@@H](CC2)NC(=O)CNC(=O)C=2C=C(C=CC=2)C(F)(F)F)CC1 NXZNYBUBXWWKCP-JMOWIOHXSA-N 0.000 description 2
• 210000002850 nasal mucosa Anatomy 0.000 description 2
• 210000001331 nose Anatomy 0.000 description 2
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
• 150000004102 olmesartan derivatives Chemical group 0.000 description 2
• 238000012015 optical character recognition Methods 0.000 description 2
• 230000003204 osmotic effect Effects 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 229910052760 oxygen Inorganic materials 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• 102000020233 phosphotransferase Human genes 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
• 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
• 239000004810 polytetrafluoroethylene Substances 0.000 description 2
• 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 230000000770 proinflammatory effect Effects 0.000 description 2
• 230000004850 protein–protein interaction Effects 0.000 description 2
• 229940044551 receptor antagonist Drugs 0.000 description 2
• 239000002464 receptor antagonist Substances 0.000 description 2
• 230000001084 renoprotective effect Effects 0.000 description 2
• 229950004871 repagermanium Drugs 0.000 description 2
• 230000004043 responsiveness Effects 0.000 description 2
• 229960002256 spironolactone Drugs 0.000 description 2
• LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 210000001562 sternum Anatomy 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 235000010487 tragacanth Nutrition 0.000 description 2
• 239000000196 tragacanth Substances 0.000 description 2
• 229940116362 tragacanth Drugs 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• 210000000626 ureter Anatomy 0.000 description 2
• 230000006439 vascular pathology Effects 0.000 description 2
• 239000005526 vasoconstrictor agent Substances 0.000 description 2
• 239000013598 vector Substances 0.000 description 2
• 235000015112 vegetable and seed oil Nutrition 0.000 description 2
• 239000008158 vegetable oil Substances 0.000 description 2
• 238000012800 visualization Methods 0.000 description 2
• IZUAHLHTQJCCLJ-UHFFFAOYSA-N (2-chloro-1,1,2,2-tetrafluoroethyl) hypochlorite Chemical compound FC(F)(Cl)C(F)(F)OCl IZUAHLHTQJCCLJ-UHFFFAOYSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• OHMHBGPWCHTMQE-UHFFFAOYSA-N 2,2-dichloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)C(Cl)Cl OHMHBGPWCHTMQE-UHFFFAOYSA-N 0.000 description 1
• 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
• IQULGZQMMPRBLA-UHFFFAOYSA-N 2-carboxyethylgermanium Chemical compound OC(=O)CC[Ge] IQULGZQMMPRBLA-UHFFFAOYSA-N 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
• PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
• 206010027654 Allergic conditions Diseases 0.000 description 1
• 208000024985 Alport syndrome Diseases 0.000 description 1
• 102000004400 Aminopeptidases Human genes 0.000 description 1
• 108090000915 Aminopeptidases Proteins 0.000 description 1
• 101800000734 Angiotensin-1 Proteins 0.000 description 1
• 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
• 102000004881 Angiotensinogen Human genes 0.000 description 1
• 108090001067 Angiotensinogen Proteins 0.000 description 1
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 241001674044 Blattodea Species 0.000 description 1
• 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
• 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
• 229940124802 CB1 antagonist Drugs 0.000 description 1
• 102000018202 CC chemokine receptor 4 Human genes 0.000 description 1
• 102000011006 CC chemokine receptor 6 Human genes 0.000 description 1
• 108010017317 CCR4 Receptors Proteins 0.000 description 1
• 108010017079 CCR6 Receptors Proteins 0.000 description 1
• 108010009575 CD55 Antigens Proteins 0.000 description 1
• 108010055167 CD59 Antigens Proteins 0.000 description 1
• 108010026667 CGP 42112A Proteins 0.000 description 1
• UXGNARZDONUMMK-LRMQDCNJSA-N CGP-42112A Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CCCCNC(=O)[C@H](CCCN=C(N)N)NC(=O)OCC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)C=1C=NC=CC=1)CC1=CN=CN1 UXGNARZDONUMMK-LRMQDCNJSA-N 0.000 description 1
• 101150051404 CGR1 gene Proteins 0.000 description 1
• 101150107986 CGR2 gene Proteins 0.000 description 1
• 208000019300 CLIPPERS Diseases 0.000 description 1
• 229940127291 Calcium channel antagonist Drugs 0.000 description 1
• 101100243090 Candida glabrata (strain ATCC 2001 / CBS 138 / JCM 3761 / NBRC 0622 / NRRL Y-65) PDH1 gene Proteins 0.000 description 1
• 241000282461 Canis lupus Species 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 208000020446 Cardiac disease Diseases 0.000 description 1
• 208000031229 Cardiomyopathies Diseases 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 102100035294 Chemokine XC receptor 1 Human genes 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 102000004266 Collagen Type IV Human genes 0.000 description 1
• 108010042086 Collagen Type IV Proteins 0.000 description 1
• 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 206010012655 Diabetic complications Diseases 0.000 description 1
• 206010054044 Diabetic microangiopathy Diseases 0.000 description 1
• 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
• 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 229920003136 Eudragit® L polymer Polymers 0.000 description 1
• 229920003137 Eudragit® S polymer Polymers 0.000 description 1
• 108010067306 Fibronectins Proteins 0.000 description 1
• 102000016359 Fibronectins Human genes 0.000 description 1
• 101150039048 GCR1 gene Proteins 0.000 description 1
• 208000022461 Glomerular disease Diseases 0.000 description 1
• 108060003393 Granulin Proteins 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000777599 Homo sapiens C-C chemokine receptor type 2 Proteins 0.000 description 1
• 101000804783 Homo sapiens Chemokine XC receptor 1 Proteins 0.000 description 1
• 101001013648 Homo sapiens Methionine synthase Proteins 0.000 description 1
• 101000890951 Homo sapiens Type-2 angiotensin II receptor Proteins 0.000 description 1
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
• 241001508558 Hypera Species 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
• 206010021263 IgA nephropathy Diseases 0.000 description 1
• 206010061216 Infarction Diseases 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 206010054805 Macroangiopathy Diseases 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 102000011721 Matrix Metalloproteinase 12 Human genes 0.000 description 1
• 108010076501 Matrix Metalloproteinase 12 Proteins 0.000 description 1
• 101710151321 Melanostatin Proteins 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 206010027525 Microalbuminuria Diseases 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 102000007474 Multiprotein Complexes Human genes 0.000 description 1
• 108010085220 Multiprotein Complexes Proteins 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 208000009525 Myocarditis Diseases 0.000 description 1
• 102400000064 Neuropeptide Y Human genes 0.000 description 1
• UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 description 1
• 239000004100 Oxytetracycline Substances 0.000 description 1
• QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 229920005439 Perspex® Polymers 0.000 description 1
• 229920001363 Polidocanol Polymers 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 206010036346 Posterior capsule opacification Diseases 0.000 description 1
• 108010024526 Protein Kinase C beta Proteins 0.000 description 1
• 102100024923 Protein kinase C beta type Human genes 0.000 description 1
• 241000084978 Rena Species 0.000 description 1
• 206010062237 Renal impairment Diseases 0.000 description 1
• 206010038910 Retinitis Diseases 0.000 description 1
• 241000220010 Rhode Species 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• 229920001800 Shellac Polymers 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 102000005157 Somatostatin Human genes 0.000 description 1
• 108010056088 Somatostatin Proteins 0.000 description 1
• 239000004147 Sorbitan trioleate Substances 0.000 description 1
• PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 235000015125 Sterculia urens Nutrition 0.000 description 1
• 240000001058 Sterculia urens Species 0.000 description 1
• 108010009583 Transforming Growth Factors Proteins 0.000 description 1
• 102000009618 Transforming Growth Factors Human genes 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 102100040372 Type-2 angiotensin II receptor Human genes 0.000 description 1
• 206010046406 Ureteric obstruction Diseases 0.000 description 1
• 206010052568 Urticaria chronic Diseases 0.000 description 1
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 238000011374 additional therapy Methods 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 239000003741 agents affecting lipid metabolism Substances 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 229960002478 aldosterone Drugs 0.000 description 1
• 201000009961 allergic asthma Diseases 0.000 description 1
• 208000002205 allergic conjunctivitis Diseases 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 230000003444 anaesthetic effect Effects 0.000 description 1
• 230000000202 analgesic effect Effects 0.000 description 1
• 238000000540 analysis of variance Methods 0.000 description 1
• 239000012491 analyte Substances 0.000 description 1
• 229940127282 angiotensin receptor antagonist Drugs 0.000 description 1
• 229960004977 anhydrous lactose Drugs 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 239000003831 antifriction material Substances 0.000 description 1
• 230000036528 appetite Effects 0.000 description 1
• 235000019789 appetite Nutrition 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 229940058087 atacand Drugs 0.000 description 1
• 238000000889 atomisation Methods 0.000 description 1
• 208000024998 atopic conjunctivitis Diseases 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 229940055053 benicar Drugs 0.000 description 1
• 239000000440 bentonite Substances 0.000 description 1
• 229910000278 bentonite Inorganic materials 0.000 description 1
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• 239000002876 beta blocker Substances 0.000 description 1
• 229940097320 beta blocking agent Drugs 0.000 description 1
• 108010080367 beta-Arrestins Proteins 0.000 description 1
• 102000000072 beta-Arrestins Human genes 0.000 description 1
• 235000013361 beverage Nutrition 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 239000004067 bulking agent Substances 0.000 description 1
• 239000000480 calcium channel blocker Substances 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• 229910000394 calcium triphosphate Inorganic materials 0.000 description 1
• FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
• 229960000830 captopril Drugs 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• WZNRVWBKYDHTKI-UHFFFAOYSA-N cellulose, acetate 1,2,4-benzenetricarboxylate Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.OC(=O)C1=CC(C(=O)O)=CC=C1C(=O)OCC1C(OC2C(C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(COC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)O2)OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)O1 WZNRVWBKYDHTKI-UHFFFAOYSA-N 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 101150054999 cgrA gene Proteins 0.000 description 1
• 229920001429 chelating resin Polymers 0.000 description 1
• 150000005829 chemical entities Chemical class 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 239000002559 chemokine receptor antagonist Substances 0.000 description 1
• 230000010252 chemokine signaling pathway Effects 0.000 description 1
• KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
• 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 208000024376 chronic urticaria Diseases 0.000 description 1
• 238000004140 cleaning Methods 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 230000024203 complement activation Effects 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 230000009918 complex formation Effects 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 229940097499 cozaar Drugs 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000000994 depressogenic effect Effects 0.000 description 1
• 201000009101 diabetic angiopathy Diseases 0.000 description 1
• 230000003205 diastolic effect Effects 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• JMGZBMRVDHKMKB-UHFFFAOYSA-L disodium;2-sulfobutanedioate Chemical compound [Na+].[Na+].OS(=O)(=O)C(C([O-])=O)CC([O-])=O JMGZBMRVDHKMKB-UHFFFAOYSA-L 0.000 description 1
• 238000002224 dissection Methods 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 239000003651 drinking water Substances 0.000 description 1
• 235000020188 drinking water Nutrition 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 239000000428 dust Substances 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 208000028208 end stage renal disease Diseases 0.000 description 1
• 201000000523 end stage renal failure Diseases 0.000 description 1
• 230000012202 endocytosis Effects 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
• SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 210000003195 fascia Anatomy 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 229910021485 fumed silica Inorganic materials 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 210000004392 genitalia Anatomy 0.000 description 1
• 208000024693 gingival disease Diseases 0.000 description 1
• 208000007565 gingivitis Diseases 0.000 description 1
• 210000000585 glomerular basement membrane Anatomy 0.000 description 1
• 231100000852 glomerular disease Toxicity 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 230000004217 heart function Effects 0.000 description 1
• 230000000004 hemodynamic effect Effects 0.000 description 1
• 208000003215 hereditary nephritis Diseases 0.000 description 1
• 229960001340 histamine Drugs 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
• 230000001631 hypertensive effect Effects 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 210000003405 ileum Anatomy 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 230000037451 immune surveillance Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 230000007574 infarction Effects 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 229940102213 injectable suspension Drugs 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 230000019948 ion homeostasis Effects 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 210000001630 jejunum Anatomy 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 229960001375 lactose Drugs 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 238000002350 laparotomy Methods 0.000 description 1
• 210000002429 large intestine Anatomy 0.000 description 1
• 229950006462 lauromacrogol 400 Drugs 0.000 description 1
• 238000002386 leaching Methods 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 201000010260 leiomyoma Diseases 0.000 description 1
• OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
• 235000020778 linoleic acid Nutrition 0.000 description 1
• 230000037356 lipid metabolism Effects 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 229940127554 medical product Drugs 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• MZEOSVPWMSEFPW-XYCDVDSTSA-N n-[2-[[(3s,4s)-1-[4-(1,3-benzodioxol-5-yl)-4-hydroxycyclohexyl]-4-ethoxypyrrolidin-3-yl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide Chemical compound N([C@H]1CN(C[C@@H]1OCC)C1CCC(O)(CC1)C=1C=C2OCOC2=CC=1)C(=O)CNC(=O)C1=CC=CC(C(F)(F)F)=C1 MZEOSVPWMSEFPW-XYCDVDSTSA-N 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 230000010807 negative regulation of binding Effects 0.000 description 1
• 201000008383 nephritis Diseases 0.000 description 1
• 210000000885 nephron Anatomy 0.000 description 1
• 201000009925 nephrosclerosis Diseases 0.000 description 1
• 208000038001 non-diabetic kidney disease Diseases 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 238000003305 oral gavage Methods 0.000 description 1
• 239000008184 oral solid dosage form Substances 0.000 description 1
• IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
• 229960000625 oxytetracycline Drugs 0.000 description 1
• 235000019366 oxytetracycline Nutrition 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• RFWLACFDYFIVMC-UHFFFAOYSA-D pentacalcium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O RFWLACFDYFIVMC-UHFFFAOYSA-D 0.000 description 1
• 208000028169 periodontal disease Diseases 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 238000002135 phase contrast microscopy Methods 0.000 description 1
• XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 230000006461 physiological response Effects 0.000 description 1
• 238000009160 phytotherapy Methods 0.000 description 1
• 229940068196 placebo Drugs 0.000 description 1
• 239000000902 placebo Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 239000004926 polymethyl methacrylate Substances 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 230000017363 positive regulation of growth Effects 0.000 description 1
• 238000010149 post-hoc-test Methods 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 210000003814 preoptic area Anatomy 0.000 description 1
• 230000009290 primary effect Effects 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 208000037821 progressive disease Diseases 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 230000004853 protein function Effects 0.000 description 1
• 230000029983 protein stabilization Effects 0.000 description 1
• 210000000512 proximal kidney tubule Anatomy 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 239000002469 receptor inverse agonist Substances 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 238000009877 rendering Methods 0.000 description 1
• 230000010410 reperfusion Effects 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 230000001932 seasonal effect Effects 0.000 description 1
• 239000004208 shellac Substances 0.000 description 1
• 229940113147 shellac Drugs 0.000 description 1
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
• 235000013874 shellac Nutrition 0.000 description 1
• 235000021309 simple sugar Nutrition 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical group [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• 229940080313 sodium starch Drugs 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
• 229960000553 somatostatin Drugs 0.000 description 1
• 102000004115 somatostatin receptor 5 Human genes 0.000 description 1
• 108090000680 somatostatin receptor 5 Proteins 0.000 description 1
• 235000019337 sorbitan trioleate Nutrition 0.000 description 1
• 229960000391 sorbitan trioleate Drugs 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 239000008347 soybean phospholipid Substances 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 238000012453 sprague-dawley rat model Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• 238000009495 sugar coating Methods 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 210000002820 sympathetic nervous system Anatomy 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 229940078806 teveten Drugs 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 230000014616 translation Effects 0.000 description 1
• 125000005591 trimellitate group Chemical group 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 210000005239 tubule Anatomy 0.000 description 1
• 208000037999 tubulointerstitial fibrosis Diseases 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 239000012178 vegetable wax Substances 0.000 description 1
• 229940070384 ventolin Drugs 0.000 description 1
• 230000007279 water homeostasis Effects 0.000 description 1
• 229920003176 water-insoluble polymer Polymers 0.000 description 1
• 229920003169 water-soluble polymer Polymers 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 229930195727 α-lactose Natural products 0.000 description 1